Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Retinal Biologics Market Growth in 2025?

Over the past few years, the retinal biologics market size has experienced significant expansion. The market, which was valued at $25.17 billion in 2024, is forecasted to reach $28.42 billion in 2025, boasting a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this historic growth include a rise in retinal disorders, an aging demographic, increased awareness leading to early diagnosis, improved healthcare infrastructure, and a surge in healthcare spending.

What Is the Forecast for the Retinal Biologics Market Size Through 2029?

Expectations are high for a swift expansion in the retinal biologics market size in the approaching years. The market is projected to surge to a value of $44.51 billion in 2029, growing at a compound annual growth rate (CAGR) of 11.9%. This anticipated growth during the forecast period is linked to broadening therapeutic applications, individualized medicine advancements, emerging market expansion, a robust biologics pipeline, collaborations & partnerships, as well as government initiatives and support. In the same forecast period, the main trends to watch include non-invasive delivery techniques, real-world evidence use, added indications, regulatory pathway simplification, and patient-focused outcomes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11911&type=smp

What are the Key Market Players in Retinal Biologics Market and How They’re Evolving?

Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.

What Are the Primary Growth Drivers in the Retinal Biologics Market?

The escalation in diabetic eye disease prevalence is anticipated to fuel the expansion of the retinal biologics market in the future. Diabetic eye disease, a diabetes complication, impacts the eyes leading to vision impairment and blindness in those with diabetes. Retinal biologics offer the potential for more specific and effective treatment alternatives, facilitating earlier intervention and enhanced results in preventing vision loss linked to diabetic eye disease. For example, information from the Australian Bureau of Statistics revealed that in 2022, 5.3% of the Australian population (approximately 1.3 million individuals) had diabetes, a substantial increase from the previous 3.3%. Consequently, the escalating incidence of diabetic eye disease is propelling the retinal biologics market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11911&type=smp

What Are the Leading Segments in the Global Retinal Biologics Industry?

The retinal biologics market covered in this report is segmented –

1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor

2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications

3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies, Small Molecule Inhibitors

2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies, Fusion Proteins

What Are the Key Market Trends in the Retinal Biologics Industry?

A primary trend growing in prevalence within the retinal biologics market is the focus on product innovation. To consolidate their market positions and establish a competitive edge, main companies within this domain are directing their efforts towards the creation of novel, pioneering products. Illustrating this, in May 2023, F. Hoffmann-La Roche Ltd., a healthcare company based in Switzerland, publicized that its supplemental biologics license application (sBLA) for Vabysmo (faricimab), aimed at retinal vein occlusion (RVO) induced macular edema, had been approved by the U.S. Food and Drug Administration. This endorsement was conferred due to favourable results from two Phase III trials which exhibited notable and sustained visual improvement with Vabysmo, reaching the primary endpoint of non-inferiority in comparison to aflibercept. Vabysmo represents the first approved bispecific antibody for eyes, designed to combat neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema. Additional investigations demonstrated a lack of blood vessel leakage in the retina in those treated with Vabysmo as compared to patients receiving aflibercept.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

What Is the Regional Outlook for the Retinal Biologics Market?

North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11911

This Report Delivers Insight On:

1. How big is the retinal biologics market, and how is it changing globally?

2. Who are the major companies in the retinal biologics market, and how are they performing?

3. What are the key opportunities and risks in the retinal biologics market right now?

4. Which products or customer segments are growing the most in the retinal biologics market?

5. What factors are helping or slowing down the growth of the retinal biologics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model